Filing Flows › Longevity Health Holdings (XAGE) › R&D spending
Longevity Health Holdings (XAGE) R&D spending by quarter
Longevity Health Holdings' R&D spending was $73K in Q2 2026 (second quarter 2026), +32% from Q1 2026. Over the last 7 quarters it ranged from $55K (Q1 2026) to $229K (Q2 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $73K | +32% | -68% |
| Q1 2026 | $55K | -47% | -72% |
| Q4 2025 | $104K | -54% | -45% |
| Q3 2025 | $228K | -0.3% | — |
| Q2 2025 | $229K | +16% | — |
| Q1 2025 | $197K | +4% | — |
| Q4 2024 | $189K | — | — |
Q2 2026 at a glance
Longevity Health Holdings, Q2 2026: revenue $396K (-21% year over year), operating margin -182.9%, net loss $1.9M, operating cash flow −$224K. The chart follows the revenue to costs, profit and cash.
Questions
What is Longevity Health Holdings' R&D spending?
Longevity Health Holdings' R&D spending was $73K in Q2 2026 (second quarter 2026), +32% from Q1 2026.
How has Longevity Health Holdings' R&D spending changed?
Over the last 7 quarters it ranged from $55K (Q1 2026) to $229K (Q2 2025).
Q2 2026 results → · How Longevity Health Holdings makes money →